These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 31287015)

  • 1. Disease activity and damage in juvenile idiopathic arthritis: methotrexate era versus biologic era.
    Giancane G; Muratore V; Marzetti V; Quilis N; Benavente BS; Bagnasco F; Alongi A; Civino A; Quartulli L; Consolaro A; Ravelli A
    Arthritis Res Ther; 2019 Jul; 21(1):168. PubMed ID: 31287015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prediction rule for lack of achievement of inactive disease with methotrexate as the sole disease-modifying antirheumatic therapy in juvenile idiopathic arthritis.
    Bava C; Mongelli F; Pistorio A; Bertamino M; Bracciolini G; Dalprà S; Davì S; Lanni S; Muratore V; Pederzoli S; Rosina S; Schiappapietra B; Suffia C; Varnier G; Verazza S; Giancane G; Consolaro A; Ravelli A
    Pediatr Rheumatol Online J; 2019 Jul; 17(1):50. PubMed ID: 31345226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A modified juvenile arthritis damage index to improve articular damage assessment in juvenile idiopathic arthritis--enthesitis-related arthritis (JIA-ERA).
    Singh YP; Aggarwal A
    Clin Rheumatol; 2012 May; 31(5):767-74. PubMed ID: 22234493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cumulative Damage in Juvenile Idiopathic Arthritis: A Multicenter Study From the Pediatric Rheumatology Arab Group.
    Al-Mayouf SM; Hashad S; Khawaja K; Alrasheedi A; Abdwani R; Abushhaiwia A; AlSuwaiti M; Alzyoud R; Al Abrawi S; Asiri A; Alshaikh M; Sharif E; Muzaffer M; Alsewairi W; Zlenti M; Kawaja E; Almutairi M; Majeed M; Lotfy H; AlMarri M; Almutairi N;
    Arthritis Care Res (Hoboken); 2021 Apr; 73(4):586-592. PubMed ID: 32886859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Juvenile idiopathic arthritis in the biologic era: predictors of the disease progression and need for early introduction of biologic treatment.
    Nalbanti P; Kanakoudi-Tsakalidou F; Trachana M; Pratsidou-Gertsi P; Farmaki E; Bamidis P; Papachristou F
    Rheumatol Int; 2018 Jul; 38(7):1241-1250. PubMed ID: 29845429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Outcomes Following Achievement of Clinically Inactive Disease in Juvenile Idiopathic Arthritis: The Importance of Definition.
    Shoop-Worrall SJW; Verstappen SMM; McDonagh JE; Baildam E; Chieng A; Davidson J; Foster H; Ioannou Y; McErlane F; Wedderburn LR; Thomson W; Hyrich KL
    Arthritis Rheumatol; 2018 Sep; 70(9):1519-1529. PubMed ID: 29648683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective study on 158 Thai patients with juvenile idiopathic arthritis followed in a single center over a 15-year period.
    Vilaiyuk S; Soponkanaporn S; Jaovisidha S; Benjaponpitak S; Manuyakorn W
    Int J Rheum Dis; 2016 Dec; 19(12):1342-1350. PubMed ID: 26176300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression of articular and extraarticular damage in oligoarticular juvenile idiopathic arthritis.
    de Oliveira Sato J; Corrente JE; Saad Magalhães C
    Clin Exp Rheumatol; 2011; 29(5):871-7. PubMed ID: 21962036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Summary of AHRQ's Comparative Effectiveness Review of Disease-Modifying Antirheumatic Drugs for Children with Juvenile Idiopathic Arthritis.
    McMahan R; Balfe LM; Greene L
    J Manag Care Pharm; 2012; 18(1 Suppl B):1-16. PubMed ID: 22376227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. When should the use of biological agents be considered in persistent oligoarticular juvenile idiopathic arthritis patients?
    Polat MC; Çelikel E; Tekin ZE; Kurt T; Kaplan MM; Güngörer V; Tekgöz N; Sezer M; Karagöl C; Coşkun S; Öner N; Sezer S; Acar BÇ
    Eur J Pediatr; 2024 Jun; 183(6):2725-2731. PubMed ID: 38554171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment prescribing patterns in patients with juvenile idiopathic arthritis (JIA): Analysis from the UK Childhood Arthritis Prospective Study (CAPS).
    Davies R; Carrasco R; Foster HE; Baildam EM; Chieng SEA; Davidson JE; Ioannou Y; Wedderburn LR; Thomson W; Hyrich KL
    Semin Arthritis Rheum; 2016 Oct; 46(2):190-195. PubMed ID: 27422803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort.
    Guzman J; Oen K; Tucker LB; Huber AM; Shiff N; Boire G; Scuccimarri R; Berard R; Tse SM; Morishita K; Stringer E; Johnson N; Levy DM; Duffy KW; Cabral DA; Rosenberg AM; Larché M; Dancey P; Petty RE; Laxer RM; Silverman E; Miettunen P; Chetaille AL; Haddad E; Houghton K; Spiegel L; Turvey SE; Schmeling H; Lang B; Ellsworth J; Ramsey S; Bruns A; Campillo S; Benseler S; Chédeville G; Schneider R; Yeung R; Duffy CM;
    Ann Rheum Dis; 2015 Oct; 74(10):1854-60. PubMed ID: 24842571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends towards more active introduction of drug therapy, emphasizing methotrexate and biologic agents, for juvenile idiopathic arthritis.
    Pohjankoski H; Kautiainen H; Lauri JV; Puolakka K; Rantalaiho V
    Clin Rheumatol; 2020 Jan; 39(1):263-268. PubMed ID: 31346886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries.
    Swart J; Giancane G; Horneff G; Magnusson B; Hofer M; Alexeeva Е; Panaviene V; Bader-Meunier B; Anton J; Nielsen S; De Benedetti F; Kamphuis S; Staņēviča V; Tracahana M; Ailioaie LM; Tsitsami E; Klein A; Minden K; Foeldvari I; Haas JP; Klotsche J; Horne AC; Consolaro A; Bovis F; Bagnasco F; Pistorio A; Martini A; Wulffraat N; Ruperto N;
    Arthritis Res Ther; 2018 Dec; 20(1):285. PubMed ID: 30587248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of disease activity, functional disability and articular damage in patients with juvenile idiopathic arthritis: a prospective outcome study.
    Susic GZ; Stojanovic RM; Pejnovic NN; Damjanov NS; Soldatovic II; Jablanovic DB; Sefik Bukilica MN
    Clin Exp Rheumatol; 2011; 29(2):337-44. PubMed ID: 21385554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Looking for the best strategy to treat children with new onset juvenile idiopathic arthritis: presentation of the "comparison of STep-up and step-down therapeutic strategies in childhood ARthritiS" (STARS) trial.
    Burrone M; Mazzoni M; Naddei R; Pistorio A; Spelta M; Scala S; Patrone E; Garrone M; Lombardi M; Villa L; Pascale G; Cavanna R; Ruperto N; Ravelli A; Consolaro A;
    Pediatr Rheumatol Online J; 2022 Sep; 20(1):80. PubMed ID: 36071444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokine Biomarkers of Disease Activity and Therapeutic Response after Initiating Methotrexate Therapy in Patients with Juvenile Idiopathic Arthritis.
    Funk RS; Chan MA; Becker ML
    Pharmacotherapy; 2017 Jun; 37(6):700-711. PubMed ID: 28475276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ovarian reserve in children with juvenile idiopathic arthritis using biologic disease-modifying anti-rheumatic drugs.
    Ozer Y; Yildiz M; Turan H; Tarcin G; Bingol Aydin D; Gunalp A; Haslak F; Kilic Konte E; Aslan E; Koker O; Bayramoglu E; Sahin S; Adrovic A; Barut K; Kasapcopur O; Evliyaoglu O
    Clin Rheumatol; 2024 Jan; 43(1):399-406. PubMed ID: 37646858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and long-term retention of anti-tumour necrosis factor treatment in juvenile and adult patients with juvenile idiopathic arthritis: data from Reuma.pt.
    Mourão AF; Santos MJ; Melo Gomes JA; Martins FM; Mendonça SC; Oliveira Ramos F; Fernandes S; Salgado M; Guedes M; Carvalho S; Costa JA; Brito I; Duarte C; Furtado C; Lopes A; Rodrigues A; Sequeira G; Branco JC; Fonseca JE; Canhão H
    Rheumatology (Oxford); 2016 Apr; 55(4):697-703. PubMed ID: 26672905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of methotrexate in children with rheumatic diseases.
    Gutiérrez-Suárez R; Burgos-Vargas R
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S122-7. PubMed ID: 21044445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.